DURECT (DRRX) Expected to Announce Earnings on Monday

DURECT (NASDAQ:DRRX) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.29 million for the quarter.

DURECT (NASDAQ:DRRX) last posted its quarterly earnings results on Wednesday, March 26th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.12). DURECT had a negative net margin of 198.58% and a negative return on equity of 300.62%. The firm had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $6.91 million. On average, analysts expect DURECT to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DURECT Stock Up 11.4 %

Shares of NASDAQ:DRRX opened at $0.73 on Friday. DURECT has a 52-week low of $0.52 and a 52-week high of $1.88. The stock has a market cap of $22.69 million, a price-to-earnings ratio of -1.20 and a beta of 0.66. The business has a 50-day moving average price of $0.74 and a 200-day moving average price of $0.87.

Wall Street Analyst Weigh In

Several research firms have recently commented on DRRX. StockNews.com started coverage on shares of DURECT in a report on Tuesday. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, March 27th.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.